Wall Street is positive on Outlook Therapeutics Inc (OTLK). On average, analysts give the stock a Strong Buy rating. The average price target is $7, which means analysts expect the stock to climb by 438.46% over the next twelve months. That average ranking earns the stock an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating OTLK a Strong Buy today. Find out what this means to you and get the rest of the rankings on OTLK!